U.S. markets closed
  • S&P 500

    3,825.33
    +39.95 (+1.06%)
     
  • Dow 30

    31,097.26
    +321.86 (+1.05%)
     
  • Nasdaq

    11,127.84
    +99.14 (+0.90%)
     
  • Russell 2000

    1,727.76
    +19.77 (+1.16%)
     
  • Crude Oil

    107.67
    -0.76 (-0.70%)
     
  • Gold

    1,809.00
    +7.50 (+0.42%)
     
  • Silver

    19.78
    +0.19 (+0.96%)
     
  • EUR/USD

    1.0454
    +0.0027 (+0.26%)
     
  • 10-Yr Bond

    2.8890
    0.0000 (0.00%)
     
  • GBP/USD

    1.2127
    +0.0024 (+0.20%)
     
  • USD/JPY

    135.4400
    +0.2650 (+0.20%)
     
  • BTC-USD

    19,226.48
    +242.47 (+1.28%)
     
  • CMC Crypto 200

    415.21
    -4.93 (-1.17%)
     
  • FTSE 100

    7,236.29
    +67.64 (+0.94%)
     
  • Nikkei 225

    26,153.81
    +218.19 (+0.84%)
     

Provention Bio Resubmits Teplizumab Application In US For Type-1 Diabetes

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Provention Bio Inc (NASDAQ: PRVB) has resubmitted the Biologics License Application (BLA) for teplizumab for the delay of clinical type 1 diabetes (T1D) in at-risk individuals.

  • The purpose of the resubmission is to address the FDA's pharmacokinetic (PK) comparability considerations contained in the complete response letter (CRL) issued last July and the Chemical, Manufacturing & Controls (CMC) and product quality considerations.

  • The CRL did not cite any clinical deficiencies related to the efficacy and safety data packages submitted to the original BLA.

  • The resubmission comes after last month's Type B meeting with the FDA. The company agreed to use PK modeling to adjust the 14-day dosing regimen for the planned commercial product to match the exposure of clinical material used in prior clinical trials by ensuring that the 90% confidence intervals for relevant PK parameters fall within the target 80-125% range.

  • The therapy narrowly passed the vote at an FDA advisory committee meeting in May last year amid questions about the small study size and more.

  • The FDA has 30 days to review the resubmission, determine whether it is complete and acceptable for review, and provide a review goal date.

  • Price Action: PRVB shares are up 1.85% at $6.60 during the market session on the last check Tuesday.

See more from Benzinga

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.